尤脱欣治疗尖锐湿疣140例疗效观察

我们于1994年9月—1995年3月应用辽宁华卫制药股份有限公司生产的尤脱欣(0.5％足叶草毒素酊)治疗尖锐湿疣140例,现将治疗结果报告如下: 临床资料 140例中,男性112例,女性28例,年龄18～58岁,病期15天至3月,均系临床表现     

尤脱欣治疗尖锐湿疣34例

自1999年1月～2000年8月,应用尤脱欣(辽宁华卫制药股份有限公司出品)治疗尖锐湿疣34例,疗效满意.现报告如下. 1资料与方法 1.1临床资料患者均为本站门诊就诊者.病例总数34例,其中男24例,女10例.年龄19～63岁,平均年龄32.9±10.7岁.已婚23例,未婚9例,离婚2例.     

尤脱欣治疗尖锐湿疣亚临床感染

我科应用尤脱欣（０．５％鬼臼毒素酊）外涂治疗尖锐湿疣（ＣＡ）亚临床感染４５例，获得了较好的疗效，现报告如下。临床资料一般资料４５例中男４１例，女４例。年龄２０～５５岁，平均２９．６岁。病程１０天～５月，平均５３．７天。既往有典型ＣＡ病史２２例，就诊时...     

激光、尤脱欣治疗尖锐湿疣447例疗效对比

我们自1993年3月～1997年12月用三种方法治疗尖锐湿疣220例，并作了对比观察，发现激光疗法和尤脱欣治疗是最佳方法，根据这一结果，从1998年1月～2002年12月用三种方法治疗尖锐湿疣并作了对比观察，现将随访到的447例报道如下。     

尤脱欣与疣敌治疗尖锐湿疣的疗效比较

我们对尤脱欣（０．５％鬼臼毒素酊，辽宁华卫制药股份有限公司生产）与进口同类药疣敌（Ｗａｒｔｅｃ）治疗尖锐湿疣的疗效进行了比较，并对其药物作用机理作了初步研究，现报告如下。一、病例与方法１．病例选择及分组：选择年龄在１８～６０岁，临床皮损典型，疣体大小在２ｃｍ以内的尖锐湿疣患者共１２９例。所有患者随机分为Ｍ组，一组外用尤脱欣，共６７例，男４６例，女２１例；另一组外用疣敌，共６２例，男３４例，女２８例。２．用药方法：连续上药３天，每天２次，然后观察４天为一疗程；疣体未消退者重复治疗，总计不超过３个疗…     

0.5%鬼臼毒素酊治疗尖锐湿疣1839例疗效观察

０．５％鬼臼毒素酊治疗尖锐湿疣１８３９例疗效观察朱学骏孔繁荣王家璧徐文严乐嘉豫顾有守李宇宁鬼臼毒素是治疗尖锐湿疣的有效药物，１９９０年世界卫生组织推荐０．５％鬼臼毒素酊为治疗尖锐湿疣的一线药物。我国在１９９３年研制成功，并用于临床。为考察０．５％鬼臼...     

0.5%鬼臼毒素酊治疗尖锐湿疣疗效观察

1994年6～9月,我们应用国家二类新药[0.5%鬼臼毒素酊(商品名尤脱欣,辽宁华卫制药股份有限公司生产)]治疗尖锐湿疣70例,获得满意疗效,现报告如一、临床资料70例均为门诊患者,全部病例均具有典型的临床特征,皮损发生在男女生殖器或肛周部位,5%醋酸白试验阳性,且治疗前一周内未使用过其它治疗本病的药物。70例中男49例,女21例;年龄19～65岁,平均33.97岁;病程3天至1年,平均3.1个月。皮损部位及分布由多至少依次为:男性冠状沟23例,龟头12例,包皮内11例,肛周10例,尿道口6例,系带4例,包皮外4例。     

0.5%鬼臼毒素酊治疗尖锐湿疣32例

我科自１９９４年１月至６月应用尤脱欣（辽宁华卫制药股份有限公司生产）治疗尖锐湿疣３２例，并以同样含０．５％鬼臼毒素的瑞典Ａｓｔｒａ大药厂出品的疣敌做为对照，收到较好的效果，现报告如下。一、临床资料所有病例均来自门诊，选择具有典型临床症状和体征，醋酸白试验阳性的患者６０例，其中３８例经病理证实。男性４２例，皮损位于阴茎、冠状沟、龟头、尿道口；女性１８例，皮损位于大阴唇、小阴唇。病程１～５个月，疣体大小０．１ｃｍ～０．８ｃｍ左右；数目１～６个不等。患者年龄２０～４０岁。将６０例患者随机分组，尤脱欣组…     

CO2激光加疣脱欣治疗尖锐湿疣疗效观察

我们于 1997年 1月至 1998年 12月采用ＣＯ2 激光加疣脱欣外用治疗尖锐湿疣取得良效 ,并与单纯ＣＯ2 激光治疗作为对照 ,结果报告如下 :1　资料与方法1 1　一般资料　 12 0例均为本院皮肤性病科初诊门诊患者 ,临床症状和体征典型 ,经 5 %醋酸白试验或病理检测确诊。其中男 5 8例 ,女 6 2例。年龄 16～ 6 3岁 ,平均 2 8 5± 6 2岁。病期 0 5月～ 2 0年 ,平均 2 0± 1 2月。已婚 6 8例 ,未婚 5 2例。有不洁性生活史或配偶患尖锐湿疣者 74例 (6 1 7% ) ,伴有其它ＳＴＤ者 14例 (11 7% )。随机分为ＣＯ2 激光加疣脱欣外用治疗组和单纯ＣＯ2 …     

疣脱欣治疗女性尖锐湿疣74例

疣脱欣治疗女性尖锐湿疣７４例焦曾霞，李亚里（北京解放军总医院妇产科，１００８５３）朱良英（北京解放军３０５医院，）李冬平（北京总后高等专科医校，）我们应用国家二类新药疣脱欣（０．５％鬼臼毒素酊）对７４例女性外生殖器ＣＡ患者进行治疗观察，取得较好疗效，...     

Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata

BACKGROUND: Genital warts are a common sexually transmitted disease caused by human papillomaviruses. Podophyllotoxin 0.5%, approved for patient self-administration, has been used most extensively in the treatment of genital warts. Imiquimod, a novel immune response modifier capable of inducing interferon-alpha and a variety of cytokines, has been examined as a potential treatment for genital warts. But 0.5% podophyllotoxin and 5% imiquimod have not been compared in any extensive and formal studies, although they are the common topical agents for genital warts. OBJECTIVE: To evaluate the efficacy and safety of topical 5% imiquimod and 0.5% podophyllotoxin in the treatment of genital warts. METHODS: We searched Medline (1966 to June 2005), Embase (1974 to June 2005) and the Cochrane Controlled Trials Register (issue 3, 2005). Randomized controlled trials of 5% imiquimod or 0.5% podophyllotoxin in the treatment of genital warts were collected. Two reviewers extracted the data and independently assessed the quality of the included medical literature. Then, meta-analysis was conducted. RESULTS: Twelve studies including 3 placebo-controlled trials of imiquimod and 9 placebo-controlled trials of podophyllotoxin were included. The clinical cure rates of imiquimod and podophyllotoxin were 50.34 and 56.41%, respectively, without statistically significant differences between the two (p > 0.05). A combined analysis of the 3 studies on imiquimod showed a statistically significant difference to the placebo group [pooled odds ratio (OR) 11.65, 95% confidence interval (CI) 6.05-22.44], as did a combined analysis of the 9 studies on podophyllotoxin (pooled OR 16.70, 95% CI 7.06-39.48). The most common adverse events of imiquimod were erythema, erosion, excoriation, itching and burning; those of podophyllotoxin were burning, pain, erosion, itching and inflammation. CONCLUSION: Imiquimod and podophyllotoxin possess similar curative effects on condylomata acuminata but podophyllotoxin has more serious adverse effects.     

患尖锐湿疣孕妇分娩方法及其治疗的探讨

报告用保守－剖宫分娩法治疗１３例孕妇尖锐湿疣，结果全部痊愈。经１￣９年的随访观察，无１例复发，她们所产的６男７女发育正常。结果表明，保守－剖宫分娩疗法既简单，方便，无痛苦，又避免了其它创伤性治疗对母婴所造成的不良影响，对患尖锐湿疣而又需要生育的孕妇来说是一种行之有效，安全可靠的方法，值得推广应用。     

儿童尖锐湿疣光动力疗法的治疗及护理

目的:观察儿童尖锐湿疣光动力治疗的疗效,探讨最佳护理方法。方法:28例6岁以下患儿疣体处外敷ALA 3小时,照射前20分钟给予10%水合氯醛口服,待患儿熟睡后采用635nm半导体激光器局部照射,光斑直径2.5cm,能量密度100J/CM2,时间20分钟。结果:28例患儿服药后10～20分钟均能很好入睡,经1～3次治疗后25例患儿疣体完全清除,清除率89.3%。结论:儿童ALA-PDT时配合应用10%水合氯醛能很好入睡,采用综合护理方法能顺利完成治疗,获得疗效,并无不良反应。     

Long-term follow-up of endoscopic therapy of anal canal condylomata acuminata with podophyllotoxin

BACKGROUND: Condylomata acuminata of the anal canal, a common sexually transmitted disease, are difficult-to-treat lesions with a high recurrence rate after initial successful treatment. OBJECTIVE: Our aim was to evaluate by anoscopy the efficacy of podophyllotoxin 0.5% solution topically applied for the treatment of anal warts. METHODS: We prospectively studied consecutive patients with condylomata acuminata of the anal canal that spared the rectum. They were treated with 0.5% podophyllotoxin solution topically applied on the warts, by anoscopy. Podophyllotoxin solution was administered on days 1, 2 and 3 every week (a treatment cycle) for a maximum of 4 weeks. Patients whose warts were not completely eradicated were classified as failures. Follow-up anoscopy was performed monthly for the first 6 months and every 6 months thereafter. Those who relapsed during the follow-up period were retreated. RESULTS: Twenty-two immunocompetent patients entered the study. The primary clearance rate was 22.7, 54.5, 68.1 and 86.3% after 1, 2, 3 and 4 treatment cycles, respectively. During the follow-up period (46, 12-60 months), seven patients (36.8%) relapsed. Four of them were successfully retreated. Thus, a complete cure was achieved in 16 out of 22 patients (72.7%). Adverse side-effects were mild. They included proctalgia in six (27.2%), bleeding in four (17.2%), and both proctalgia and bleeding in two (9%) patients. CONCLUSIONS: Endoscopic topical application of 0.5% podophyllotoxin solution is an effective and well-tolerated method for the treatment of condylomata acuminata of the anal canal.     

Self-treatment using a 0.5% podophyllotoxin cream of external genital condylomata acuminata in women. A placebo-controlled, double-blind study.

In a double-blind, placebo-controlled study, self-treatment with a 0.5% podophyllotoxin cream was evaluated among 60 women afflicted solely with outer vulvoanal warts; 12 women received treatment with placebo cream and 48 women with active substance, administered twice daily in 3-day cycles once weekly for up to 3 weeks. Patients who were not completely cured after three cycles were classified as treatment failures. Four patients treated with podophyllotoxin cream were excluded: two were considered drop-outs, another patient was concurrently afflicted with intraanal warts, and a fourth patient refused further therapy with the cream due to the severity of local side effects occurring from the first course of therapy. Of the remaining 44 patients treated with active substance, the primary cure rates were 43%, 66%, and 91% after 1, 2, and 3 treatment cycles, respectively. Within a 3-month follow-up period, 6 (14%) patients who were originally considered cured exhibited some degree of either "recurrence" or "reoccurrence". Thus, a complete and permanent cure from podophyllotoxin cream occurred in 38 out of 44 patients (77%). Placebo lacked therapeutic influence. A slight-to-moderate tenderness, pain, burning, or all of the above in the treated areas was noted by more than 60% of the women who were treated with the podophyllotoxin cream.     

A randomized clinical comparative study of cryotherapy plus photodynamic therapy vs. cryotherapy in the treatment of multiple condylomata acuminata

Background: Cryotherapy cannot destroy subclinical human papillomavirus‐infected cells of condylomata acuminata (CA). The topical application of aminolevulinic acid (ALA) results in a shallow penetration depth in CA lesions ( 1 ). Objectives: To compare the efficacy and safety of cryotherapy plus ALA‐photodynamic therapy (PDT) with cryotherapy in the treatment of multiple CA. Methods: Eighty patients with multiple CA received cryotherapy plus ALA‐PDT (n=40) or cryotherapy plus placebo‐PDT (n=40). After cryotherapy, a 20% ALA or a placebo solution was applied to the CA area 3 h before illumination with red light (635 nm, 100 mW/cm², 100 J/cm²). The treatment was repeated 7 days after the first treatment if the lesions were not completely resolved. The complete response rate, recurrence rate and adverse effects in the two groups were analyzed. Results: After two treatments, the complete response rates in the combined group (cryotherapy plus ALA‐PDT) and cryotherapy group were 32.4% (36/111) and 32.6% (43/132) in the anal area (P>0.05), 100% (32/32) and 54.5% (18/33) in the urethral meatus (P<0.05), and 94.2% (129/137) and 50.5% (56/111) in the external genitals (P<0.05), respectively. The recurrence rates in the combined group and cryotherapy group were 24.3% (27/111) and 31.1% (41/132) in the anal area (P>0.05), 9.4% (3/32) and 39.4% (13/33) in the urethral meatus (P<0.05), and 3.6% (5/137) and 31.5% (35/111) in the external genitals (P<0.05), respectively. The adverse effects in each group included mild to moderate pain, edema, erosion and hypopigmentation, without any infection, ulcers, scarring or urethral malformations. Conclusion: Cryotherapy plus ALA‐PDT is a more effective regimen for the treatment of multiple CA compared with cryotherapy alone.     

以5-氨基酮戊酸诱导荧光定位诊断尖锐湿疣的临床研究

目的 探讨5-氨基酮戊酸(ALA)诱导的荧光诊断法在诊断尖锐湿疣(CA)亚临床感染中的价值.方法 临床随机选择25例CA患者,在其疣体及周围5 cm范围进行外用20%ALA乳膏并封包,在2 h和4 h时以410nm蓝光观察用药部位红斑面积.并对相同部位进行醋酸白试验,观察结果.结果 25例患者中,疣体ALA阳性率为100%,醋酸白试验阳性率为80%;疣体周围ALA阳性率为96%,醋酸白试验阳性率为8%.合适的检测时间为敷药后2 h.但黏膜及炎症部位仍存在一定的假阳性.结论 ALA在CA的疣体及其周围亚临床感染的诊断中优于传统的醋酸白试验,在CA的诊断和鉴别诊断中具有一定价值.     

Successful topical treatment of anal giant condylomata acuminata in an infant

Anogenital condylomata acuminata are induced by human papillomavirus (HPV) and they rarely manifest in immunocompetent children. Therapeutic options depend on patient's age and general conditions and extension of the lesions. However, management is still a challenge and recurrences are frequent. Cryotherapy, laser, and surgical treatments in children are painful and frequently require general anesthesia. Imiquimod is a topical immune response modifier and constitutes a noninvasive alternative for the treatment of anogenital condylomata acuminata. Here, we report an infant admitted to our hospital with a giant vegetative papillomatous lesion on the perianal region surrounded by small satellites papules. PCR for HPV confirmed the clinical diagnosis of giant condylomata acuminata due to HPV type 6. The child has been successfully treated with topical 5% imiquimod cream without side effects. Although topical imiquimod is not licensed for pediatric age, this report highlights the potential benefits of its use in selected pediatric cases.     

5％咪喹莫特乳膏治疗尖锐湿疣Meta分析

目的以循证医学的方法对5％咪喹莫特乳膏治疗尖锐湿疣的疗效与安全性进行系统评价。方法检索PubMed、Ovid、Web of Seience、UMI、Elsevier以及Cochrane图书馆、中文科技期刊数据库（CNKI）、中国生物医学文献数据库（CBMDisc），纳入比较5％咪喹莫特乳膏与安慰剂或氟尿嘧啶乳膏的随机对照试验，南两名评价者独立提取资料并进行方法学质量评估。试验数据的统计分析采用Cochrane协作网提供的RevMan4．2培软件进行。结果最终纳入8个临床随机对照试验，对5％咪喹莫特乳膏治疗尖锐湿疣进行了Meta分析，与安慰剂组相比，差异具有统计学意义；与氟尿嘧啶乳膏组相比．疗效差异无统计学意义，没有报道与5％咪喹莫特乳膏临床应用相关的严重系统性不良反应。结论现有临床证据表明，5％咪喹莫特乳膏治疗尖锐湿疣有确切的疗效与较好的安全性。